Truman Milling, MD
Emergency Medicine · Austin, TXNPI 1134187172
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by CSL Behring at 48.3% of the total. Reporting peaked in 2022 at $24,885 and has fallen 68.9% since, to $7,749 in 2023. Among emergency medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $1552.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$29K
- Astrazeneca UK Limited$13K
- AstraZeneca$8K
- Instrumentation Laboratory Company$6K
- AMAG Pharmaceuticals, Inc.$2K
- Portola Pharmaceuticals, LLC$1K
- plus $816 from 2 others
Across 159 payments — averaging $5991.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Portola Pharmaceuticals, LLC$283K
- AstraZeneca$281K
- E.r. Squibb & Sons, L.L.C.$184K
- CSL Behring$100K
- Genentech, Inc.$81K
- Boehringer Ingelheim$18K
- plus $5K from 1 others
What the payments were for
- Consulting fees$17,70929%
- Speaking & faculty fees$31,10751%
- Travel & lodging$10,99118%
- Food & beverage$6401%
- Education$1100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 9 | $29,225 |
| Astrazeneca UK Limited | 8 | $13,343 |
| AstraZeneca(2 entities) | 9 | $7,726 |
| Instrumentation Laboratory Company | 6 | $6,039 |
| AMAG Pharmaceuticals, Inc. | 1 | $2,200 |
| Portola Pharmaceuticals, LLC | 4 | $1,209 |
| Boehringer Ingelheim International GmbH | 1 | $805 |
| Chiesi USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,557 in reported general payments places this provider in the 95th percentile of 3,952 emergency medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 54 | $466 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $353 |
| Ibuprofen | 57 | $228 |
| Ondansetron OdtOndansetron | 14 | $161 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $140 |
| Cyclobenzaprine Hcl | 26 | $99 |
| Azithromycin | 20 | $81 |
| Ciprofloxacin Hcl | 11 | $75 |
| Prednisone | 41 | $66 |
Paid to pharmacies, not to this prescriber.
Other emergency medicine in Austin
- Arthur AbelloAustin$204K
- Nadav MorAustin$26K
- Steven ConroyAustin$20K
- John McKinneyTyler$1.9M
- William PeacockHouston$513K
- Myiesha TaylorSunnyvale$369K
- James WilliamsSan Antonio$360K
- Armando MolinaEl Paso$290K
- Farid DharamsiDallas$159K
- David RobinsonHouston$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.